Lenalidomide Cooper

Lenalidomide, the active ingredient in Lenalidomide Cooper, is a immunomodulatory agent presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients, offering antineoplastic and anti‑angiogenic benefits.

GNH USA supplies Lenalidomide Cooper as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across multiple regions. Customers benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Lenalidomide is employed in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma cells and dysplastic clones.

- Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Myelodysplastic Syndromes: reduces transfusion dependence and delays progression to acute leukemia in patients with del(5q) cytogenetic abnormality. - Mantle Cell Lymphoma: enhances response rates when combined with rituximab in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: upset stomach often occurring after dosing. - Rash: mild skin eruptions or itching.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury.

When prescribing Lenalidomide, clinicians should consider several safety precautions. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thrombosis prophylaxis: assess need for anticoagulation in patients with risk factors. - Renal impairment: adjust monitoring and dosing in patients with reduced kidney function. - Hepatic function: monitor liver enzymes regularly during therapy. - Store at ambient temperature: keep tablets below 25°C in original container, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce Lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with Lenalidomide.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - Immunosuppressants (e.g., cyclosporine): heightened risk of infection. - Vaccines: live attenuated vaccines may be less effective; avoid during therapy.